Interzol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Interzol

Property Description
Active Ingredient Ketoconazole
Pharmacological Class Antifungal Agent (Antimycotic)
Forms Tablet, Cream, Shampoo, Foam, Gel
Common Use Control or elimination of fungal/yeast infections
Origin Synthetic Compound

What is Interzol: Defining the Antifungal Agent

Interzol is a pharmaceutical product containing the active ingredient Ketoconazole, and it is defined pharmacologically as an azole antifungal agent. The medication's general purpose is to control or eliminate infections caused by various pathological fungi and yeasts. The substance belongs to the broader class of azole derivatives, structurally similar to imidazole. Its classification as an antifungal agent signifies its primary benefit in addressing microbial overgrowth and helping restore the body’s normal microbial balance. Pharmacological studies have clinically recognized this compound for its effectiveness in managing a wide range of fungal pathologies.

Composition and Origin: Ketoconazole as a Synthetic Imidazole

The foundation of Interzol is the active ingredient Ketoconazole, which is a synthetic compound manufactured in a laboratory, not naturally sourced. Chemically, the molecule features an imidazole structure. This synthetic origin allows for a predictable and reliable therapeutic effect, as the compound is precisely engineered to target a specific biological process in the fungal cell. This process is known as the inhibition of ergosterol synthesis, meaning the medicine essentially prevents the fungus from producing the necessary building blocks for its protective outer membrane.

Available Forms and Therapeutic Differentiation

Ketoconazole is formulated into several distinct dosage forms to accommodate the varied locations of fungal infections, providing both topical preparation and systemic medication options. Topical preparation forms, such as Cream or Shampoo, are intended for direct, external application to the skin or scalp and are often available over-the-counter (OTC) in lower concentrations, targeting localized issues. In contrast, the Systemic medication form, which is a Tablet, is generally classified as prescription-only (Rx) and is designed for oral administration and subsequent absorption into the bloodstream to address more widespread or internal fungal issues. This difference in administration route represents a key therapeutic differentiation.

Regulatory References

  1. DailyMed: Ketoconazole

What side effects are possible with Interzol?

Possible Side Effects and Safety Information

The official safety profile for Interzol (Ketoconazole) varies significantly depending on the formulation, being separated into risks for the systemic tablet and localized reactions for topical preparations.

Serious Adverse Reactions (Systemic Tablet)

Official regulatory documents emphasize the risk of Serious Hepatotoxicity, which has been documented to include cases resulting in fatal outcomes or requiring liver transplantation. The systemic tablet is also associated with the risk of QT Prolongation when co-administered with certain drugs, potentially leading to dangerous ventricular dysrhythmias. Endocrine concerns include the possibility of Adrenal Insufficiency.

Common Adverse Reactions and System-Organ Classes

The systemic tablet is formally classified with Common effects affecting several System-Organ Classes. These frequently reported events include Nausea, Vomiting, Abdominal pain, Diarrhoea, and effects on the nervous system such as Headache and Dizziness. Less common effects include Gynecomastia and Impotence.

Topical Safety and Constraints

Adverse effects for the cream, foam, or shampoo are mostly localized, with Skin Burning Sensation and Pruritus (itching) being commonly documented application site reactions. The systemic tablet is generally contraindicated in patients with pre-existing liver disease. Safety data for the systemic tablet are not established in children under 12 years of age. Hepatic injury has been noted to occur at both treatment initiation and within the first six months of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with the systemic (oral tablet) form of Interzol (Ketoconazole) may result in severe, documented physiological complications, particularly involving the liver and heart. Officially recognized manifestations include acute liver injury (hepatotoxicity), which carries a risk of fatal outcome, and serious cardiovascular effects such as QT prolongation leading to life-threatening ventricular dysrhythmias. Other systemic concerns include signs of adrenal insufficiency, such as hypotension (low blood pressure) and hypoglycemia (low blood sugar), along with seizures and loss of consciousness.


Emergency Actions Required

Immediate medical attention is mandated when systemic overdose is suspected. Emergency services (911) must be contacted immediately if a person has collapsed, had a seizure, has trouble breathing, or exhibits a fast, irregular heartbeat. The overall regulatory approach to management is supportive and symptomatic care. For oral ingestion, activated charcoal may be considered within the first hour. Specific regulatory guidance notes that patients presenting with signs of adrenal insufficiency may require the administration of hydrocortisone along with saline and glucose infusion.

In contrast, excessive use of the topical formulations is documented to cause localized effects such as erythema (redness) and a burning sensation, which typically resolve upon discontinuation. Accidental ingestion of the topical liquid forms requires supportive measures, and gastric lavage is not to be performed due to the risk of aspiration.

Therapeutic Uses of Interzol

What Interzol Treats: Main Uses and Benefits

The primary therapeutic utility of Interzol (Ketoconazole) is applied to help with supportive management for symptom management across several clinical domains, generally helping to manage symptoms that interfere with daily functioning.

Relief from Superficial Skin and Scalp Discomfort

This domain helps address symptom clusters that may become intense or disruptive, such as itching, redness, scaling, and flaking. It is relevant for managing conditions like seborrheic dermatitis, ringworm (tinea corporis), Athlete's foot (tinea pedis), and pityriasis versicolor. Interzol is commonly used to help with these recurrent or episodic manifestations. When appropriate, use may contribute to improved day-to-day comfort by contributing to easing the overall symptom load of these visible and highly distracting skin manifestations.

“The goal of management is to provide symptomatic relief and supports general well-being during symptomatic phases.”

Support for Severe Systemic Diseases and Specialized Conditions

Interzol is considered relevant in clinical settings that involve acute or unstable symptom patterns, offering supportive relief when symptoms become temporarily overwhelming from serious, deep-seated fungal infections (such as blastomycosis). In these situations, Interzol may offer symptomatic relief that supports patients during difficult episodes, assisting with the overall symptom load related to systemic infection. It is also considered relevant for easing symptoms related to the specialized endocrine condition, Cushing's syndrome.


Quick Fact: Relief for Scaling and Flaking Interzol is commonly used to help manage the characteristic flaking and scaling symptoms associated with conditions like seborrheic dermatitis and dandruff.

Eligibility and Restrictions for Use

The systemic use of Interzol (Ketoconazole oral tablet) is strictly governed by regulatory eligibility rules. The medicine is allowed only for adults with specific, life-threatening systemic fungal infections when alternative therapies are unavailable or not tolerated. Use for common fungal infections of the skin or nails is not recommended.

Eligibility Status Non-Eligibility Criteria (Contraindications)
Prohibited Patients with acute or chronic liver disease or pre-treatment liver enzyme levels above a defined threshold.
Patients with congenital or acquired QTc prolongation (a specific cardiac condition) or known hypersensitivity to the drug.
Pregnancy, breastfeeding, and women of childbearing potential who are not using effective contraception.

Restricted Use and Special Groups: Interzol is not used for fungal meningitis due to poor drug penetration. Caution and monitoring are required for patients with pre-existing adrenal insufficiency or those under prolonged stress. For children, the potential for long-term therapy to affect puberty and fertility must be carefully considered.

What should I know about interactions with other medicines?

Interzol Interactions with other medicines and products

Interzol (Ketoconazole oral tablets) has an officially documented interaction profile centered on its designation as a potent inhibitor of the CYP3A4 enzyme and drug transporters like P-glycoprotein (P-gp). This characteristic causes elevated plasma concentrations and prolonged effects for numerous co-administered drugs.

Classification Interaction Examples (Official Labeling)
Formal Contraindication Co-administration is prohibited with select antiarrhythmics (e.g., Quinidine, Dofetilide), HMG-CoA reductase inhibitors (e.g., Simvastatin, Lovastatin, Atorvastatin), oral benzodiazepines (e.g., Oral Midazolam, Alprazolam), and ergot alkaloids (e.g., Ergotamine). These are disallowed due to the risk of life-threatening events like QT prolongation, rhabdomyolysis, or prolonged sedation.
Exposure Modification Concurrent use with potent CYP3A4 inducers (e.g., Rifampin) is restricted as it significantly reduces Ketoconazole plasma levels (AUC and Cmax), potentially leading to failure. Conversely, Interzol increases the exposure of many other medicines (e.g., Immunosuppressants, Warfarin, Sildenafil) that are CYP3A4 substrates.
Timing Requirements Antacids must be administered at least 1 hour before or 2 hours after Interzol. For co-administration with gastric acid secretion suppressors, Interzol absorption may be maintained by concurrent intake with an acidic beverage.
Substance Restrictions Alcohol consumption is prohibited due to the documented increased risk of liver damage and potential for a disulfiram-like reaction. Consumption of Grapefruit/Grapefruit Juice should be avoided as it can increase Ketoconazole plasma levels.

Mechanism of Action

Inhibition of Fungal Cell Membrane Synthesis

Interzol's core mechanism is the inhibition of the fungal enzyme lanosterol 14alpha-demethylase ( CYP51), an essential step in the pathogen's ergosterol synthesis pathway. The molecule binds to the enzyme's heme iron, effectively blocking the conversion of lanosterol. By this action, the drug prevents the formation of ergosterol, a necessary membrane component, and simultaneously causes the accumulation of toxic intermediate sterols.


Structural Collapse and Pathogen Growth Cessation

The resulting depletion of ergosterol and the buildup of toxic materials severely compromises the fungal cell's structural integrity, increasing its membrane permeability and impairing essential cellular functions. This process leads to the cessation of pathogen growth (fungistatic action) and, at higher drug concentrations, fungicidal action. This targeted cellular effect is the necessary physiological modulation that prevents the propagation of the pathogenic organism.

Dosage and Administration Information

How to use Interzol

Interzol (Ketoconazole) is administered via two distinct routes: Oral (as 200 mg tablets) for systemic fungal infections, and Topical (as creams or shampoos) for localized dermal or scalp conditions.


Dosing and Frequency

For systemic adult use, the starting dose is 200 mg taken once daily, which may be increased to 400 mg daily. Specialized uses, such as for certain endocrine conditions, may follow regimens of up to 1,200 mg per day administered in two or three divided doses. Topical formulations are generally applied once or twice daily for defined courses, followed by an as-needed schedule for maintenance.

Administration Conditions

The absorption of the oral tablet is dependent on an acidic environment; therefore, it must be taken with a meal to ensure maximal systemic exposure. If a patient exhibits reduced gastric acidity, instructions indicate that the dose be taken with an acidic beverage (such as non-diet cola). Furthermore, acid-neutralizing agents, like antacids, must be separated from the tablet by at least one hour before or two hours after the dose to prevent chemical interference.

Course Duration and Age Rules

Treatment duration is explicitly defined for various conditions. Systemic therapy typically requires approximately six months to complete. Pediatric dosing for children ge 2 years of age is calculated based on body weight, using a specified range of 3.3 to 6.6 mg/kg once daily. No specific dosage adjustment is typically documented for patients with renal impairment.

Recent Clinical Evidence

Research evidence / Overview of Studies for Interzol

Evidence for Superficial Skin and Scalp Fungal Conditions

Research exploring the topical use of Interzol has primarily relied on short-term, randomized controlled trials (RCTs) and systematic reviews. These studies examined outcomes related to physical discomfort, including scaling, itching, and redness (erythema), alongside monitoring for mycological cure in adults and adolescents. The trials documented measurements of symptom change over defined time intervals, typically lasting only a few weeks. What remains uncertain involves the long-term data and the persistence of these patterns, as follow-up durations were limited in many studies.

Evidence for Severe Systemic Fungal Infections

The research base for the oral tablet form in treating severe endemic mycoses is rooted in historical randomized trials and comparative studies conducted in high-risk patient groups. This evidence was evaluated in contexts involving outcomes related to systemic imbalance, such as the incidence of fungal colonization and patterns of clinical clearance. Findings across this historical research were mixed. The certainty remains low regarding the generalizability of the evidence today due to limitations like small sample sizes and inconsistency across studies. This aligns with its highly restricted regulatory use.

Evidence for the Specialized Endocrine Condition (Cushing's Syndrome)

Research examining Interzol for the management of hypercortisolism is primarily based on retrospective observational cohort studies and extensive case series, not prospective, randomized trials. Researchers monitored the primary biochemical measure: the normalization of urinary free cortisol (UFC) levels in adult and adolescent patients. The evidence is limited because it is largely retrospective and observational, meaning the certainty remains low. Data for certain subgroups, especially those with specific underlying causes, remain insufficient.

What is Still Uncertain About the Research Base

A key limitation is the reliance on observational settings for the specialized endocrine indication, not randomized controlled trials. Furthermore, the evidence quality varies across studies for systemic fungal infections, and the comparative evidence is lacking when assessing its performance against newer, alternative treatments. Follow-up durations are limited for superficial conditions, and data for certain pediatric or high-risk groups remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Interzol (FAQ)


Q: How quickly does Interzol start to show effects after taking it?

A: Official information regarding the oral tablet notes that peak concentrations of the active ingredient in the bloodstream are typically reached within 1 to 2 hours after a single dose is taken with a meal. This pharmacokinetic data indicates when the drug is most available in the body to begin its action.


Q: Are there any specific foods or drinks to avoid while taking Interzol?

A: Yes, official regulatory warnings advise that both grapefruit and grapefruit juice should be avoided because they can increase the drug's plasma levels. Furthermore, consumption of alcohol is prohibited due to a documented increased risk of liver damage when combined with the oral tablet.


Q: How long does a course of treatment with Interzol usually last?

A: The required duration of therapy can vary depending on the condition being treated. For systemic fungal infections, treatment with the oral tablet typically requires approximately six months to complete. Topical formulations may be used for a defined course followed by an as-needed schedule for maintenance.


Q: Is Interzol safe to use during pregnancy or while breastfeeding?

A: Regulatory documents formally list the use of the oral tablet as contraindicated, meaning it is prohibited during both pregnancy and while breastfeeding due to potential risks to the fetus or infant. These are established eligibility rules outlined in the product label.


Q: Does Interzol need to be taken with food, or can it be taken on an empty stomach?

A: Official instructions state that the medicine should be taken with a meal to ensure maximal absorption into the body. Regulatory instructions indicate that if a patient exhibits reduced gastric acidity, the dose may be taken with an acidic beverage (such as non-diet cola) to maintain absorption.


Q: Is Interzol used for preventing future issues or just treating current ones?

A: The systemic form of the drug is primarily used for treating current, active infections. However, topical formulations are often applied for an initial course followed by an as-needed schedule, which may function for the long-term control or maintenance of certain recurring conditions.


Q: Is there a generic version of Interzol available?

A: Yes. The active ingredient in Interzol is Ketoconazole, which is the official generic name for the compound. Multiple generic versions of this drug have been approved by regulatory agencies and are available on the market.


Q: What should I do if I accidentally miss a dose of Interzol?

A: If a dose is missed, the general guidance found in patient instructions is to skip the missed dose entirely and return to the regular dosing schedule. Regulatory instructions generally advise against taking two doses together to compensate for a missed dose.


Q: Is Interzol safe for older adults (seniors) to take?

A: Official data on the use of the oral tablet in patients older than 65 years of age are limited. However, regulatory sources have not indicated that a specific dose adjustment is required for the elderly population.


Q: Does Interzol affect blood pressure?

A: While changes in blood pressure are not listed as a common side effect, official warnings note that a serious adverse effect is adrenal insufficiency. Regulatory guidelines indicate that blood pressure monitoring is required in patients who have or are at risk of developing adrenal insufficiency.


Q: Can Interzol be used to treat infections in children?

A: The systemic tablet is approved for use in adolescents above the age of 12 years for certain specific indications. However, regulatory agencies state that safety data for the systemic tablet are not established for children under 12 years of age.


Q: Is there any research that shows Interzol is effective for long-term use?

A: Clinical trials for the systemic use of the oral tablet are limited. Regulatory warnings state that serious liver damage has occurred in patients receiving low doses for long periods. Follow-up durations are often limited in studies for superficial conditions.


Q: What studies support the use of Interzol for its main indication?

A: The evidence base for severe systemic fungal infections is rooted in historical randomized trials and comparative studies. For the specialized endocrine indication, the supporting research is primarily based on retrospective observational cohort studies and extensive case series.


Q: Is it possible for Interzol to cause skin reactions or a rash?

A: Yes. Official product information notes that hypersensitivity reactions, which can include a skin rash and urticaria (hives), have been reported in patients taking the oral tablet.


Q: Can I take Interzol if I am also taking an antidepressant?

A: Interzol is known to be a potent inhibitor of the CYP3A4 enzyme. This characteristic means it can increase the blood concentrations of many other co-administered medicines, including certain antidepressants. The product label specifies that all concomitant medicines should be reviewed by a healthcare provider.


Q: Do I need any special monitoring (like blood tests) while taking Interzol?

A: Official regulatory warnings emphasize that due to the risk of serious liver toxicity, the patient’s liver status must be assessed before starting the oral tablet and monitored regularly (e.g., via blood tests for liver enzymes like ALT and AST) throughout treatment.


Q: What are the guidelines for using Interzol in patients with kidney issues?

A: Regulatory documents indicate that although data are limited, the way the drug is processed by the body is not significantly different in patients with renal failure. Therefore, no specific dose adjustment is generally recommended for patients with kidney issues.


Q: Can Interzol cause headaches or migraines?

A: Headache is formally listed as a common adverse reaction associated with the systemic oral tablet in official safety information.


Q: Are there any dietary restrictions specifically mentioned for Interzol users?

A: Yes. Official product warnings prohibit the consumption of alcohol and grapefruit products (juice or whole fruit). These restrictions are in place to reduce the risk of increased drug levels and potential liver damage.


Q: Is it normal to feel a bit nauseous when first starting Interzol?

A: Nausea is listed in the official safety profile as a common adverse reaction associated with the systemic oral tablet, which can occur throughout the treatment course.


Q: Is Interzol a long-term maintenance drug or a short-term treatment?

A: The drug serves both roles depending on the form. The systemic oral tablet is typically used for defined, short-term courses (e.g., up to six months). However, the topical form may be used on an as-needed schedule for the long-term control and maintenance of certain recurring skin conditions.


Q: Does Interzol have any effects on weight, either gain or loss?

A: Official safety information notes that weight loss, or anorexia, is listed as a potential symptom of serious adverse events like liver damage or adrenal insufficiency, which are associated with the oral tablet.

How should Interzol be stored and disposed of?

Storage and Handling Requirements

Official regulatory guidelines require Interzol to be stored at controlled room temperature, typically between 20 C and 25 C. The product must be kept in its original container, tightly closed, and protected from light and excessive moisture. For safety, it must be stored out of the sight and reach of children at all times.

Stability and Disposal

Stability rules for certain topical forms (like cream) require the product to be discarded if not used within 3 months of opening. When disposing of unused or expired Interzol, regulatory instructions prohibit flushing the medicine down the toilet or pouring it into a drain. Disposal must follow official government-approved drug take-back programs or specific instructions for household trash to minimize environmental impact and prevent misuse.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Interzol found in:

A-Z Index: